Maxim Group Maintains Buy on Health In Tech, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 67.0%

Neg 67% Neu 0% Pos 0%

Maxim Group analyst Allen Klee maintains Health In Tech (NASDAQ:HIT) with a Buy and lowers the price target from $4 to $3.